RetroSense Therapuetics Logowhite spacerGo to about RetroSenseGo to Investors and Partners pageGo to Product DevelopmentGo to Therapeutics AreasGo to Frequently Asked QuestionsGo to Contact Page
left image bandRight Image band
photoRetroSense Therapeutics develops game-changing gene therapy solutions to restore partial sight for certain eye diseases.

To find out more about RetroSense Therapeutics, please click through to the Contact Us page. We are currently seeking accredited financial partners and strategic partners interested in collaborating with us to develop our lead candidate.
 


Visit us on facebook.
Link to FaceBook


 

 

 

 

 

 

 

 

 

RetroSense Therapeutics is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions.

The RetroSense gene therapy technology has been demonstrated to confer light sensitivity to retinal nerve cells and restore functional vision in animal studies. Our lead product candidate, RST-001, will be developed initially for RP with advanced dry-AMD as a follow-on indication. RST-001 is not currently in human clinical trials. Please visit us periodically to see how we are making progress in vision restoration.

 

 

 

 
Font Size

News & Updates

January 12, 2015: Press Release
RetroSense Therapeutics to Present at 7th Annual Biotech Showcase Conference

January 8, 2015: Press Release
RetroSense Therapeutics Raises $6 million in Series A Financing to Further Develop Lead Product RST-001 for Retinitis Pigmentosa

November 20, 2014: Press Release
RetroSense Therapeutics Receives Second “Top Project to Watch” Nomination

November 17, 2014: Press Release
RetroSense Therapeutics Signs License Agreement with Massachusetts General Hospital, Expanding Its Optogenetics Intellectual Property Portfolio

October 30, 2014: Press Release
RetroSense Therapeutics Granted Orphan Drug Designation for Lead Product RST-001 for Retinitis Pigmentosa

June 29, 2014: Article
Gene therapy for blindness gets attention of investors
Crain's Detroit Business, June 2014

October 28, 2013: Press Release
RetroSense Therapeutics Selected by Windhover as a "Top Project to Watch: Most Licensable Product"

March 27, 2013: Press Release
RetroSense Therapeutics Announces Exclusive Option to Intellectual Property Covering Vision Augmentation from Massachusetts General Hospital

March 5, 2013: Press Release
RetroSense Therapeutics Announces Notice of Allowance for New U.S. Patent Application Broadly Covering Optogenetic Approaches to Vision Restoration

February 18, 2013: Article
How Neuroscience Will Fight Five Age-Old Afflictions

October 4, 2012: Press Release
RetroSense Therapeutics Welcomes Dr. Steven Bramer as Chief Development Officer

August 28, 2012: Article
Company Aims to Cure Blindness with Optogenetics